# Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)

> **NCT03944252** · PHASE2 · UNKNOWN · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 54 (estimated)

## Conditions studied

- Squamous Cell Anal Carcinoma

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT03944252
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-18
- **Primary completion:** 2021-02
- **Final completion:** 2022-02
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2019-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03944252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03944252, "Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03944252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*